Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SUL 238

Next Previous
Drug Profile

SUL 238

Alternative Names: SUL-238

Latest Information Update: 20 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sulfateq
  • Developer Gen Ilac; Sulfateq
  • Class Anti-infectives; Antidementias; Antiparkinsonians; Heart failure therapies; Small molecules; Urologics
  • Mechanism of Action Mitochondrial protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease
  • Phase I Alzheimer's disease
  • Preclinical Acute kidney injury; Chronic heart failure; Pulmonary arterial hypertension; Sepsis
  • Research Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Mar 2026 Phase-II clinical trials in Parkinson's disease (Treatment-naive) in Netherlands (PO) (NCT07322887)
  • 13 Jan 2026 Gen Ilac plans a phase II SHEPHERD trial for Parkinson's disease in Netherlands (PO, Tablet) in March 2026 (NCT07322887)
  • 27 Nov 2025 GEN Ilac and Sulfateq completes a phase I trial in Alzheimer's disease (In volunteers) in Turkey (PO) (NCT06277492)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top